A drop of blood can reveal how a tumor in the lungs is behaving. Doctors have long noticed that when the disease retreats, some blood markers rise while others fall. But tying these changes into a single coherent picture has been elusive.
Now, researchers have built a model that tracks three blood components at once: albumin (a protein that nourishes cells), lactate dehydrogenase (an enzyme released by damaged cells), and neutrophils (immune defense cells). The model describes how the tumor and these three markers influence each other, like gears in a clock. One moves faster, another slower, but together they tick off the time of the disease.
These aren't just numbers. Instead of a black box that spits out "how much time is left," the doctor gets an understandable mechanism: which specific blood changes point to a good or poor prognosis. This transparency helps tailor treatment to the individual and accelerates the testing of new drugs.
Lactate dehydrogenase is an enzyme that leaks out of damaged cells. When a tumor grows aggressively, its blood levels spike like smoke rising from a fire.
In Star Trek, the medical tricorder scans a patient in seconds and delivers a diagnosis. Our model is a step toward such a device — except instead of a scanner, it uses a routine blood test.